Allergan, Inc.

Todd M Heidelbaugh

Ken Chow

Phong X Nguyen

Michael E Garst

Daniel W Gil

Santosh C Sinha

Larry Allen Wheeler

John E Donello

Dario G Gomez

Smita S Bhat

Wenkui Ken Fang

John R Cappiello

Ling Li

Janet A Takeuchi

Dale A Harcourt

Daniel Gill

James A Burke

Evelyn G Corpuz

Stephen A Munk

Karen M Kedzie

Daniel W Gil Gil

John E Donello Donello

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an &#x3b1;-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.

Methods of treating &#x3b1; adrenergic mediated conditions

The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Coumarin compounds as receptor modulators with therapeutic utility

Methods of treating alpha adrenergic mediated conditions

The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Compounds as receptor modulators with therapeutic utility

Disclosed herein is a compound having a structure compositions, methods, and medicaments related thereto are also disclosed.

Therapeutic compounds

The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.

Selective subtype alpha 2 adrenergic agents and methods for use thereof

The invention provides oxazolidine and thiazolidine derivatives that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors. 

A compound having selective modulating activity at the alpha 2B and/or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1:  The compounds of Formula 1 can be incorporated in pharmaceutical compositions and used in methods of treatment of alpha 2 receptor mediated diseases and conditions.

Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors

The present invention relates to novel derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

The present invention relates to novel cyclic amine and cycloalkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Growing community of inventors

Fountain Valley, CA, United States of America

Todd M Heidelbaugh